Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
arcticnovartis
- New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland
- Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees
- Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients
Basel, February 6, 2026 – Novartis today broke grou
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
arcticnovartis
Ad-hoc-Mitteilung gemäss Art. 53 KR
Geschäftsjahr
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Full year
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis
- Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1
- Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care
- Novartis plans to submit to health authorities globally starting in early 2026
ADDRESS
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
CALL US
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
